NCT02985320View on ClinicalTrials.gov

Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

708

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Poliomyelitis
Interventions
BIOLOGICAL

Single-dose regimen of high dosage investigational sIPV

The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..

BIOLOGICAL

Single-dose regimen of medium dosage investigational sIPV

The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..

BIOLOGICAL

Three-dose regimen of high dosage investigational sIPV

The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..

BIOLOGICAL

Three-dose regimen of medium dosage investigational sIPV

The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..

BIOLOGICAL

Three-dose regimen of low dosage investigational sIPV

The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..

BIOLOGICAL

Three-dose regimen of commercialized sIPV

The control vaccine was manufactured by Chinese Academy of Medical Sciences.

BIOLOGICAL

Three-dose regimen of commercialized IPV

The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).

Trial Locations (1)

221300

Pizhou City Center for Disease Control and Prevention, Xuzhou

All Listed Sponsors
lead

Sinovac Biotech Co., Ltd

INDUSTRY

NCT02985320 - Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine | Biotech Hunter | Biotech Hunter